Therefore, blocking the aberrant activation of the NF-κB and MAPK signaling pathways while maintaining the anti-inflammatory phenotype of macrophages has pivotal roles in the prevention and treatment of IBD. Here, NFKB1 is linked to inflammatory bowel disease.